P609: CLINICOBIOLOGICAL CHARACTERISTICS AND TREATMENT EFFICACY OF NOVEL AGENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH IGLV3-21R110

• P. Hengeveld,
• Y. E. Ertem,
• J. Dubois,
• C. Mellink,
• A.-M. van der Kevie-Kersemaekers,
• L. Evers,
• K. Heezen,
• P. M. Kolijn,
• O. Mook,
• M. M. Motazacker,
• K. Nasserinejad,
• S. Kersting,
• P. Westerweel,
• C. Niemann,
• A. Kater,
• A. Langerak,
• M.-D. Levin

Affiliations

P. Hengeveld

1 Department of Immunology, Erasmus MC, Rotterdam

Y. E. Ertem

1 Department of Immunology, Erasmus MC, Rotterdam

J. Dubois

3 Department of Hematology

C. Mellink

4 Department of Human Genetics, Amsterdam UMC, Amsterdam

A.-M. van der Kevie-Kersemaekers

4 Department of Human Genetics, Amsterdam UMC, Amsterdam

L. Evers

3 Department of Hematology

K. Heezen

1 Department of Immunology, Erasmus MC, Rotterdam

P. M. Kolijn

1 Department of Immunology, Erasmus MC, Rotterdam

O. Mook

4 Department of Human Genetics, Amsterdam UMC, Amsterdam

M. M. Motazacker

4 Department of Human Genetics, Amsterdam UMC, Amsterdam

K. Nasserinejad

5 Department of Hematology, Erasmus MC, Rotterdam

S. Kersting

6 Department of Hematology, Haga Ziekenhuis, Den Haag, Netherlands

P. Westerweel

2 Department of Internal Medicine, Albert Schweizer Ziekenhuis, Dordrecht

C. Niemann

7 Department of Hematology, Rigshospitalet, Copenhagen, Denmark

A. Kater

3 Department of Hematology

A. Langerak

1 Department of Immunology, Erasmus MC, Rotterdam

M.-D. Levin

2 Department of Internal Medicine, Albert Schweizer Ziekenhuis, Dordrecht